NCT03806179已完成1 期
A Phase 1b Open-label Study of Betalutin in Combination With Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma (Archer-1)
Nordic Nanovector2 个研究点 分布在 2 个国家目标入组 7 人开始时间: 2018年10月4日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 7
- 试验地点
- 2
- 主要终点
- Safety and Tolerability: Frequency and Severity of Adverse Events (CTCAE v4.03)
研究概览
简要总结
This study is a Phase 1b, open-label, single arm dose escalation study of Betalutin followed by rituximab in patients with previously treated follicular lymphoma. The purpose of this study is to characterise the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of Betalutin in combination with rituximab.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must be ≥18 years at the time of signing the informed consent
- •ECOG performance status of 0-2
- •Histologically confirmed diagnosis (by 2008 World Health Organization [WHO] classification) of follicular lymphoma (grade 1, 2 or 3a)
- •At least one (but not more than 3) prior regimens with an anti-CD20 antibody (alone or in combination with chemotherapy), with documented relapsed, refractory disease (must not be anti-CD20 antibody-refractory) or PD
- •Presence of at least one bi-dimensionally measurable lesion by CT or MRI: longest diameter (LDi) >1.5 cm for a nodal lesion; LDi >1.0 cm for an extranodal lesion within 28 days prior to start of treatment
- •Normal organ and bone marrow function defined as:
- •Absolute neutrophil count ≥1.5 x 109/L;
- •Platelet count ≥150 x 109/L;
- •Haemoglobin ≥9 g/dL;
- •Total bilirubin ≤1.5 x upper limit of normal (ULN) (except patients with documented Gilbert's syndrome [<3.0 mg/dL]);
- •Aspartate transaminase (AST); Alanine transaminase (ALT) or Alkaline phosphatase (ALP) ≤2.5 x ULN (or ≤5.0 x ULN if liver involvement by primary disease);
- •Adequate renal function as demonstrated by a serum creatinine within the upper limit of normal range
- •Bone marrow involvement by lymphoma <25%
- •Life expectancy >3 months
- •Negative hepatitis B, hepatitis C and human immunodeficiency virus (HIV) screening tests
- •Patients must agree to use effective contraception for 12 months following last study drug administration
- •Exclusion criteria:
- •Previous haematopoietic stem cell transplantation (autologous and allogenic)
- •Evidence of histological transformation from FL to DLBCL at time of screening.
- •Previous total body irradiation
- •Chemotherapy, immunotherapy or investigational therapy within 28 days before the start of study drug administration (corticosteroid treatment at doses of ≤20 mg/day, topical or inhaled corticosteroids, granulocyte colony-stimulating factor [G-CSF] or granulocyte-macrophage colony-stimulating factor [GM CSF] are permitted up to 2 weeks prior to start of study treatment) or failure to recover from AEs associated with prior treatment
- •Previous treatment with radioimmunotherapy
- •Patients who are receiving any other investigational medicinal products
- •Known or suspected central nervous system (CNS) involvement of lymphoma
- •History of a previous treated cancer except for the following:
- •adequately treated local basal cell or squamous cell carcinoma of the skin
- •cervical carcinoma in situ
- •superficial bladder cancer or localised prostate cancer undergoing surveillance or surgery
- •localised breast cancer treated with surgery and radiotherapy but not including systemic chemotherapy
- •other adequately treated Stage 1 or 2 cancer currently in CR
- •Pregnant or lactating women
- •Exposure to another CD37 targeting drug
- •A known hypersensitivity to RTX, lilotomab, Betalutin or murine proteins or any excipient used in RTX, lilotomab or Betalutin
- •Receipt of live, attenuated vaccine within 30 days prior to enrolment
- •Evidence of severe or uncontrolled systemic diseases (e.g. ongoing infection, respiratory, cardiac, hepatic or psychiatric conditions) which in the Investigator's opinion would compromise the protocol objectives
排除标准
- 未提供
研究组 & 干预措施
10 MBq/kg Betalutin with rituximab treatment
Experimental
10 MBq/kg Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
干预措施: 10 MBq/kg Betalutin (Drug)
15 MBq/kg Betalutin with rituximab treatment
Experimental
15 MBq/kg Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
干预措施: 15 MBq/kg Betalutin (Drug)
结局指标
主要结局
Safety and Tolerability: Frequency and Severity of Adverse Events (CTCAE v4.03)
时间窗: 12 weeks
Safety and tolerability of Betalutin in combination with rituximab as determined by the frequency and severity of adverse events (CTCAE v4.03) in the first 12 weeks after Betalutin
次要结局
- Preliminary Anti-tumour Activity(25 months)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Treatment of lymphoma with targeted internal radiation therapy (Betalutin) in combination with rituximabFollicular lymphomaMedDRA version: 20.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004506-18-NOordic Nanovector ASA25
已完成
1 期
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaNCT02077166Pharmacyclics LLC.138
已完成
1 期
Phase I Study of BEBT-209 in Women With Advanced Breast CancerAdvanced Breast CancerNCT06047184BeBetter Med Inc100
终止
1 期
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)Acute Myelogenous LeukemiaMyelogenous LeukemiaTreatment Naive AMLNCT02203773AbbVie212
已完成
1 期
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsTumor, SolidNCT04840394Eikon Therapeutics1